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Hepatocyte growth factor (HGF), through Met receptor binding, fulfils numerous functions in invasive tumour growth (survival/
proliferation, motility, apoptosis), but epigenetic control of gene expression in this process is poorly understood. In HGF-treated
breast cancer cells we studied (a) the chemoinvasion towards CXCL12 (ligand of the chemokine-receptor CXCR4) and (b) the
mechanistic basis, that is, the transduction pathways that regulate CXCR4-mediated invasion, and the role played by histone
deacetylases (HDACs) after blockade with trichostatin A (TSA). In highly invasive and metastatic MDA-MB231 cells HGF had a dual
inhibitory effect, reducing spontaneous migration and specific chemoinvasion towards CXCL12, the latter by decreasing CXCR4
transactivation and protein level. After HGF the levels of phosphorylated (therefore active) c-Src and Akt persistently increased,
indicating a role of these signal transducers in the HGF-dependent cellular and molecular effects. c-Src wild-type expression vector
(Srcwt) increased active c-Src and mimicked the HGF-dependent inhibition of CXCR4 transactivation. Our findings indicate that
HDACs participated in the HGF-inhibitory effects. In fact, blockade of HDACs hindered the HGF- and Srcwt-dependent reductions
of CXCR4 transactivation and invasiveness, while inhibition of endogenous c-Src was additive with HGF, further reducing specific
chemoinvasion. In conclusion, in MDA-MB231 cells HDAC blockade with TSA partly counteracted the HGF-dependent effects
through molecular events that included enhancement of the expression of the genes for invasiveness Met and CXCR4 (depending on
serum conditions), reduction of endogenous phospho-c-Src/c-Src and phosphoAkt/Akt ratios and triggering of apoptosis. The
potential therapeutic use of TSA should take into account the variable aggressiveness of breast carcinoma cells and
microenvironment signals such as HGF at the secondary growth site of the tumour. It was interesting that HGF reduced motility
and CXCR4 functionality only of MDA-MB231 cells, and not of low-invasive MCF-7 cells, suggesting a mechanism implicated in
metastatic cell homing.
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Hepatocyte growth factor (HGF) is a multifunctional cytokine
produced by cells of the supportive tumour microenvironment, and
a central regulator of the invasive/metastatic phenotype of neoplastic
cells (Matsumoto and Nakamura, 2006; Mazzone and Comoglio, 2006;
Desiderio, 2007). Through Met receptor binding, HGF aberrantly
activates the motility/chemoinvasion, proliferation/survival and
apoptosis that characterize the epithelial-mesenchymal transition of
aggressive carcinomas. The HGF/Met couple controls the expression
of a panel of genes important for these processes, including HIF-1a
(the inducible subunit of HIF-1 transcription factor), members of the
plasminogen activation system and the C-X-C motif receptor 4
(CXCR4) (Desiderio, 2007; Gordan and Simon, 2007).
Chemokine receptor CXCR4 is involved only in some partially
clarified steps of carcinoma (breast, prostate) metastatic process
(Balkwill, 2004; Darash-Yahana et al, 2004), and silencing CXCR4
blocks breast cancer metastasis (Liang et al, 2005). Organs that are
the first destination of breast cancer metastases have high levels of
CXCL12, the CXCR4-specific ligand (Balkwill, 2004). The expres-
sion of CXCR4 is lower in lymph node metastases than in primary
breast cancer (Shim et al, 2006). In low (MCF-7) and highly
(MDA-MB231) invasive breast carcinoma cells (Guo et al, 2002;
Yang et al, 2007), HGF respectively raises and lowers the
expression of CXCR4 (Matteucci et al, 2005).
The MDA-MB231 cell line is derived from pleural effusion fluid
and is used as a model for metastatic cell migration. In view of its
gene expression profile and strong invasive behaviour in vitro, this
is a highly dedifferentiated mesenchymal-like cell line, which has
lost most epithelial markers and character, and expresses mst1
consistent with the strong metastatic behaviour (Betapudi et al,
2006). In MDA-MB231 cells, histone deacetylase 3 (HDAC3) and
phospho-c-Src colocalize at the cell membrane level early after
HGF exposure (Matteucci et al, 2007), but the possible correlation
with the reduction of CXCR4 level has never been established and
the functional significance for invasiveness has not been explained.
Histone deacetylases participate in the aberrant epigenetic
control of gene expression in tumours through deacetylation of
histones and numerous transcription factors, as well as cytosolic
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sproteins, regulating cell proliferation, cell cycle and apoptosis
(Carey and La Thangue, 2006; Ropero and Esteller, 2007). We set
out to verify whether in HGF-exposed breast carcinoma cells,
HDACs were important for invasive growth by regulating gene
expression, motility and apoptosis, depending on the tumour
aggressiveness.
This paper focuses on chemoinvasion towards CXCL12 in
invasive/metastatic MDA-MB231 breast carcinoma cells after HGF
treatment, looking into the mechanistic basis, which might differ
from MCF-7 cells. We examined the signal-transduction pathways
that might possibly regulate the changes of CXCR4 transactivation
and protein levels, and invasiveness after HGF, and the role of the
HDACs. Trichostatin A (TSA), a hydroxamic-based compound
that inhibits Class I and II HDACs (Cameron et al, 1999), was used
to assess the involvement of HDACs. Histone deacetylases are
considered important cancer targets, and HDAC inhibitors hold
out promise as a new class of anticancer drugs (Carey and La
Thangue, 2006). Trichostatin A shows antitumour activity against
breast cancer in vivo and in vitro (Yoshida et al, 1990; Vigushin
et al, 2001; Blagosklonny et al, 2005).
The tyrosine kinase c-Src and the downstream effectors ERK1/2
and Akt lie along the HGF/Met signal-transduction pathway
(Mazzone and Comoglio, 2006), and might be involved in the
regulation of NF-kB transcription factor (Huang et al, 2003a;
deGraffenried et al, 2004; Arthur, 2008). Nuclear factor-kB leads to
an increase in the invasive capacity of breast and ovarian tumour
cells (Hagemann et al, 2005), plays a critical role in CXCR4
expression (Maroni et al, 2007) and regulates apoptosis (Beere,
2004). In view of the possible interaction between NF-kB and ETS1
transcription factors on CXCR4 promoter (Maroni et al, 2007), we
studied ETS1 transactivating activity under our experimental
conditions.
We found that in HGF-treated highly invasive MDA-MB231
cells, HDACs and the enhanced/prolonged c-Src phosphorylation
were molecular events responsible for the decrease of CXCR4
expression through NF-kB and the reduction of chemoinvasion.
Trichostatin A only partly counteracted HGF-inhibitory effect on
chemoinvasion because it enhanced CXCR4 expression by ETS1
activation/c-Src activity reduction, but triggered apoptosis through
inhibition of the Akt/NF-kB pathway. The diminished CXCR4
function at the secondary growth site, where HGF seems to be
produced (Matsumoto and Nakamura, 2006; Benvenuti and
Comoglio, 2007), probably has biological implications: the homing
of metastatic cells such as MDA-MB231, attracted by CXCL12,
might be enhanced if HGF reduced their motility.
MATERIALS AND METHODS
Materials
Fetal bovine serum (FBS), RPMI-1640, TSA and AMD3100 were
from Sigma Chemical Co. (St Louis, MO, USA). Recombinant
human HGF and anti-CXCR4 monoclonal antibody (MAB-182)
were from R&D Systems (Abingdon, UK). Anti-acetyl-histone H4,
anti-histone H4, anti-heterochromatin protein 1g (HP1g) (clone
42s2), anti-phosphotyrosine (clone 4G10), anti-c-Src (clone GD11)
and anti-phospho-c-Src(Tyr 416) antibodies were from Upstate
Biotechnology (Lake Placid, NY, USA). Alexa Fluor568 secondary
antibody and JC-1 kit were from Molecular Probes (Eugene, OR,
USA). Anti-phospho-Akt (Ser473) and Anti-phosphoMet
(Tyr1349) antibodies were from Cell Signalling (Beverly, MA,
USA). Anti-Met (C-12), anti-Akt1/2 (H136), anti-ERK1/2 (K-23),
anti-phosphoERK1/2 (E-4), anti-p53 (DO-1), anti-p21 (C-19) and
anti-vinculin antibodies were from Santa-Cruz Biotechnology
(Santa Cruz, CA, USA). Fugene 6 was from Roche Applied Science
(Mannheim, Germany). Lipofectamine 2000 was from Invitrogen
(Milan, Italy). pRL-TK (Renilla luciferase) was from Promega
(Madison, WI, USA). SU6656 (c-Src inhibitor), 1L-6-hydroxy-
methyl-chiro-inositol-2-(R)-2-O-methyl-3-O-octadecylcarbonate
(Akt inhibitor) and PD 98059 (MEK inhibitor) were from
Calbiochem (Darmstadt, Germany).
Cell cultures and treatments
Human breast carcinoma cells MCF-7 and MDA-MB231 (European
Cell Cultures Collection, Salisbury, UK), routinely maintained in
RPMI-1640 medium containing 10% FBS, were starved (0.1% FBS)
for 18–24h before HGF treatment (Matteucci et al, 2005).
Trichostatin A was prepared as a 1mgml
 1 stock solution in
absolute ethanol, and stored at  201C until use (Matheu et al,
2005). Dose–response experiments were carried out with TSA,
evaluating the effect on histone H4 acetylation, and 2.5mM caused
strong enhancement while 0.1mM had no effect on H4 acetylation,
as reported (Matheu et al, 2005). In addition, 2.5mM TSA caused
dissociation of HP1g from chromatin and loss of heterochromatin
(Supplementary Figure 1A and B). Thus, we tested the two TSA
doses on the different parameters.
Transient transfection and luciferase reporter assay
We used the gene reporters pCXCR4( 2632/þ86)Luc,
p0.38SRCLuc cloned in the pGL2-enhancer vector (Dehm et al,
2004; Maroni et al, 2007), and NF-kBLuc containing three NF-kB
consensus sequences from M Hung (Anderson Cancer Center,
Houston, TX, USA). The gene reporter construct p0.38SRCA1-CAT
(kindly given by K Bonham, Saskatchewan Cancer Agency,
Saskatoon, Canada) was cut with ScaI and HindIII, and the
fragment excised was subcloned in PGL2-enhancer vector,
previously cut with SmaI and HindIII. The ETS1Luc containing
five ETS1 consensus sequences was prepared from p600Luc
construct (Maroni et al, 2007), by deleting two bases (the third
and fourth C) inside the p65 consensus site core (TCCC) with the
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA) and the following PCR primers: forward 50-TCC
CCTGGGCTTCAAGCCGCGCACCTCT; reverse 50-AGAGGTGCGC
GGCTTGAAGCCCAGGCGA. The cells, in 24-multiwell plates, were
transfected with a DNA/Fugene 6 mixture containing 200ng of
each promoter construct and 40ng Renilla luciferase (for normal-
isation) per well, treated with TSA and collected 1 or 2 days later.
Some cells were exposed concomitantly for 1 day to 2.5mM TSA
and 2mM c-Src inhibitor (SU6656) (Blake et al, 2000) or 1mg per
well dominant negative for c-Src (SrcK295M) or ETS1 (DEBHHB,
DETS1) (kindly given by WC Horne, Yale University, New Haven,
CT, USA and J Ghysdael, Institut Curie, Orsay, France). Some
TSA-treated cells were transfected with 200ng per well c-Src wild-
type (Srcwt) expression vector from S Parson (University of
Virginia, Charlottesville, VA, USA). For 1-day HGF treatment
(200ngml
 1), the cells were previously starved overnight with or
without 2.5 or 0.1mM TSA, or 2mM c-Src inhibitor or 8mM Akt
inhibitor (Hu et al, 2000; Cheng et al, 2005), or were transfected
with c-Src dominant negative. Firefly/Renilla luciferase activity
ratios were calculated by the software, using the readings obtained
with the dual luciferase assay system (Promega). Transfection
efficiency was 20–25% for MCF-7 and MDA-MB231 cells,
evaluated in b-galactosidase-stained cells (Matteucci et al, 2007).
Transfection of small interfering RNA (siRNA)
Transfection of siRNA (200pmolml
 1) targeting against Met
was carried out according to the manufacturer’s instructions
(Dharmacon Inc., Lafayette, CO, USA) using lipofectamine 2000
(Song et al, 2007). As a control, to assess the specificity of the
effects, we used antiluciferase siRNA. Two days after transfection,
with or without TSA during the last day, the cells were used for
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stotal protein extraction with urea lysis buffer, followed by western
blot analysis.
Tumour cell chemoinvasion assay
Matrigel invasion chambers from BD Biocoat Cellware (Becton
Dickinson Labware, Bedford, MA, USA) were used. Starved cells
(8 10
4 per well), either untreated or pretreated for 1 day with
HGF (200ngml
 1) with or without 2.5mM TSA, AMD3100
(1mgml
 1) (Uchida et al, 2007) or protein kinase inhibitors, were
seeded in the top chamber and CXCL12 (200ngml
 1 of medium
without serum) was added to the bottom chamber. After 22h
incubation in a humidified tissue culture incubator, non-invading
cells were removed from the top, and invading cells were stained
with Diff-Quick (Dade Bering, Switzerland). Ten fields under
 200 magnification were randomly selected and counted
(Matteucci et al, 2005).
Fluorescence microscopy
The cells (4 10
4), seeded on sterile coverslips placed in
24-multiwell plates, were starved with or without 2.5mM TSA,
treated with HGF (200ngml
 1), fixed with 4% paraformaldehyde
solution and permeabilised with 0.2% Triton X-100. They were
then incubated with anti-HP1g antibody (1:1000) for 2h, followed
by reaction with Alexa Fluor568 secondary antibody (1:800), and
nuclear staining with DAPI (1:2000). Using a fluorescence
microscope (Leica TCS SP2-A0BS), the images were collected at
 400 magnification and displayed on a computer screen. Ten
fields under  200 magnification were randomly selected and
counted (Matteucci et al, 2005).
Western blot assays and immunoprecipitation
experiments
Starved cells were treated with 2.5 or 0.1mM TSA with or without
HGF (200ngml
 1) for 1 or 2 days. Some cells were treated for 1
day with c-Src or Akt inhibitor. Total proteins or nuclear proteins,
enriched in histones, were extracted. Western blots of total
proteins (100mg) and nuclear proteins containing histones (5mg)
were carried out with respectively 10–12 and 20%
SDS–polyacrylamide gels (Yoshida et al, 1990; Nair et al, 2004;
Matteucci et al, 2007). Immunoblots were carried out with anti-
acetyl-histone H4 (2mgml
 1), anti-histone H4 (0.5mgml
 1), anti-
CXCR4 (5mgml
 1), anti-Met (1:200), anti-phosphoMet (1:1000),
anti-caspase 3 (1:1000), anti-caspase 8 (1:1000), anti-Bax (1:500),
anti-Akt1/2 (1mgml
 1), anti-phosphoAkt1/2 (1:1000), anti-ERK1/
2 (1:200), anti-phosphoERK1/2 (1:200), anti-c-Src (1mgml
 1),
anti-phospho-c-Src (2mgml
 1), anti-p53 (1:1000) or anti-p21
(1:1000). To confirm equal loading of total and nuclear proteins,
the membranes were immunoblotted respectively with anti-
vinculin and anti-histone H4 antibodies (Nair et al, 2004;
Matteucci et al, 2007). Total protein extracts (1mg of protein)
were immunoprecipitated with 2mg of anti-Met antibody. For
comparison of the two cell lines, the filters were concomitantly
hybridised and manipulated in the subsequent passages. The
signals, detected using an enhanced chemiluminescence kit (ECL
or ECL-plus; Amersham Biosciences, Amersham, UK), were
evaluated by densitometric analysis. Then the relative amounts
of proteins were calculated (Matteucci et al, 2005).
JC-1 mitochondrial membrane potential detection and flow
cytometry
We used the fluorescent cationic dye 5,50,6,60-tetrachloro-1,10,3,30-
tetra-ethyl-benzamidazolycarbocyanin iodide (JC-1) for in situ
detection of mitochondrial membrane transition events in live
cells, which provides early initiation of cellular apoptosis,
according to the manufacturer’s instructions. In non-apoptotic
cells, JC-1 is in the monomeric form in the cytosol (green) and also
accumulates as aggregates in the mitochondria (red). In apoptotic
and necrotic cells, JC-1 exists only in the monomeric form and
stains the cytosol (green). Starved MCF-7 and MDA-MB231 cells
were treated with 2.5 or 0.1mM TSA for 1 and 2 days. The cells were
incubated with JC-1 at 371C in the dark for 1h, then analysed with
a flow cytometer (Flomax, Partec, Mu ¨nster, Germany).
Statistical analysis
Luciferase activity, densitometric values and the number of
migrated cells were analysed by analysis of variance, with
Po0.05 considered significant. Differences from controls were
evaluated on original experimental data.
RESULTS
HGF had opposite effects on the invasiveness of
MDA-MB231 and MCF-7 cells involving HDACs
To see whether HGF affected the invasiveness of highly invasive
MDA-MB231 cells differently from low-invasive MCF-7 cells, cell
migration experiments were carried out with a Matrigel invasion
chamber, which is considered an in vitro model system for
metastasis (Liang et al, 2004; Matteucci et al, 2005) (Figure 1A).
When indicated, the chemoattractant CXCL12 was added in the
bottom chamber to induce CXCR4-positive breast cancer cell to
invade through the Matrigel (specific chemoinvasion). Concomi-
tant TSA treatment was carried out to evaluate HDAC involvement
in these changes.
In Figure 1A, representative images are reported (corresponding
to columns b, f, g, h of the histograms). The main findings referred
to MDA-MB231 cells (lower histogram), which migrated sponta-
neously (7.5 10
2 cells in 10 fields) (column a) and even more
(25 10
2) with CXCL12 in the bottom chamber (column b). HGF
pretreatment caused a diminution (60%) of spontaneously
migrated cells (column c vs a), suggesting that this cytokine might
affect the mesenchymal (motile) phenotype depending on b1-
integrin binding to collagen and ECM-degrading enzymes (Wolf
et al, 2008). In addition, the specific chemoinvasion towards
CXCL12 was 96% lower in HGF-pretreated cells (column g vs b),
consistent with the reduced CXCR4 level, as reported later in this
paper. Trichostatin A co-treatment partly prevented the inhibitory
effect of HGF (column h vs g), indicating that HDACs were
involved. The 40% reduction of CXCL12-mediated chemo-
invasion after TSA (column f vs b), however, might be due to its
proapoptotic role and a possible direct effect on motility (Boyault
et al, 2007).
In contrast, the low-invasive MCF-7 cells did not migrate
through the Matrigel-coated filter, either with or without CXCL12
in the bottom chamber (see Figure 1 upper histogram, columns a
and b). Pretreatment with HGF, TSA or both increased the
responsiveness to CXCL12 (columns f, g and h), and the cells
displayed significant chemoinvasion properties: the number of
migrated cells in 10 fields ranged from 20 to 30.
In preliminary experiments, we found that CXCL12 induced the
migration of breast cancer cells through Matrigel in a dose-
dependent manner. The optimal invasive response under our
experimental conditions was with 100–200ngml
 1 CXCL12 (not
shown). Lower doses (50–100ngml
 1, Fernandis et al, 2004) and
higher ones (400ngml
 1, Liang et al, 2004) are generally used to
evaluate MDA-MB231 cell chemoinvasion. Pretreatment of breast
carcinoma cells with 100 or 200ngml
 1 HGF caused similar
changes in invasiveness (not shown).
In MDA-MB231 cells, AMD3100, a competitive antagonist of
CXCL12, did not modify basal invasiveness, but completely
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sprevented CXCL12-mediated chemoinvasion and also hindered the
effect of TSA in HGF-treated cells (Figure 1B).
Mechanistic insights of the changes of invasiveness after
HGF
To clarify the mechanistic basis of the changes of invasiveness after
HGF, and the role of the HDACs, we studied the pattern of CXCR4
transactivation and protein levels and the expression of Met in
cells exposed to HGF plus 2.5mM TSA (Figure 2).
The cells were transiently transfected with the gene reporter
driven by the CXCR4 promoter( 2632/þ86)Luc, and three
treatments were established: TSA in medium containing 10%
FBS for 1 or 2 days (i); TSA in medium containing 0.1% FBS for 2
days (ii) and added with HGF during the last day (iii) (Matheu
et al, 2005; Matteucci et al, 2007) (Figure 2A). Some signalling
pathways, such as Akt, possibly implicated in CXCR4 expression
after HGF treatment, may be influenced by serum (Gort et al,
2006).
As shown in Figure 2A, in MDA-MB231 cells HGF reduced the
basal luciferase activity of starved cells (by about 40%); the
addition of TSA prevented this inhibition. CXCR4Luc activity was
not affected by 2-day TSA treatment under starvation, while TSA
increased CXCR4 transactivation (2–4-folds) in the presence of
10% FBS. Culture conditions seemed therefore to affect the cell
signalling implicated in the regulatory role of HDACs in CXCR4
transactivation. Consistently, only in serum-maintained MDA-
MB231 cells, TSA raised CXCR4 protein level (about three-fold)
(Figure 2B). To evaluate the involvement of HDACs in HGF effect
on CXCR4 protein levels, the cells were starved to prevent
interference from serum growth factors (Figure 2C). In MDA-
MB231 cells, HGF lowered the CXCR4 protein level (by about
80%); the combination with TSA almost completely prevented this
effect, although TSA alone did not affect the CXCR4 protein level,
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Figure 1 Effect of HGF and role of HDACs in the invasiveness of breast carcinoma cells. (A) MCF-7 and MDA-MB231 cells pretreated with HGF
(200ngml
 1) for 1 day, with or without 2.5mM TSA, were used for the Matrigel invasion assay, with CXCL12 (200ngml
 1) in the bottom chamber.
To estimate invasion, we counted the invading cells on the lower side of the membrane after staining ( 200 magnification of selected fields). Representative
images, corresponding to columns b, f, g and h of the histograms, are shown. The histograms report the number of migrated cells in 10 fields. The
experiments were repeated eight times, and the means±s.e. are shown. *Po0.05, **Po0.005 and ***Po0.001 vs respective starved cells;
DPo0.05 vs
HGF-pretreated cells; 111Po0.001 vs CXCL12 exposed cells. (B) Some MCF-7 and MDA-MB231 cells, pretreated with HGF for 1 day, were exposed to
2.5mM TSA with or without AMD3100 (1mgml
 1). The histograms report the number of migrated cells in 10 fields. The experiments were repeated eight
times, and the means±s.e. are shown. *Po0.05 and ***Po0.001 vs respective starved cells;
DPo0.05 vs HGF-pretreated cells;
þþPo0.005 and
þþþPo0.001 for AMD3100-treated vs AMD3100-untreated cells.
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sgiving values similar to those of starved (st) cells. The experiments
were repeated five times, as reported in Figure 2C.
All these findings in MDA-MB231 cells differed from MCF-7 cells,
in which HGF alone or with TSA strongly enhanced CXCR4
transactivation, independently of serum (Figure 2A), and raised the
CXCR4 protein level (Figure 2B and C). The dose of 0.1mM TSA did
not boost gene reporter activity in either cell line (data not shown).
In conclusion, our experimental conditions also modified
carcinoma cell invasiveness by affecting CXCR4. Basal CXCR4Luc
activity and protein level were higher in MDA-MB231 than MCF-7
cells. The increases after TSA were, however, bigger in MCF-7 than
MDA-MB231 cells, indicating possible differences of HDAC
activities and/or their role in the regulation of CXCR4 promoter
in the two lines. Possibly in TSA-treated MDA-MB231 cells the
activity of signalling pathway(s) and/or transcription factor(s)
regulated downstream limit CXCR4 transactivation. Histone
deacetylase blockade with TSA in HGF-treated MDA-MB231 cells
partly relieved the inhibition of CXCL12-mediated chemoinvasion
also by affecting CXCR4. In MCF-7 cells, HGF had stimulatory
effects similar to TSA, but invasion through Matrigel under the two
stimuli never reached that of MDA-MB231 cells, indicating that
CXCR4 receptors were partly functional.
Met protein level was about 20-fold higher in MDA-MB231 than in
MCF-7 cells (Figure 2D): in MDA-MB231 cells TSA enhanced (2–3-
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Figure 2 Changes in CXCR4 and Met expression after HGF treatment implicated HDACs. (A) The cells were transiently transfected with
pCXCR4( 2632/þ86)Luc. Some starved cells, treated with 2.5mM TSA, were added with HGF (200ngml
 1) for 1 day. The other cells in 10% serum were
treated with 2.5mM TSA for 1 or 2 days. The histograms indicate the absolute values for ratios of Firefly/Renilla luciferase activity. The data are the
means±s.e. of three independent experiments performed in triplicate. **Po0.005 and ***Po0.001 vs respective control value;
DPo0.05 vs HGF-treated
MDA-MB231 cells. (B) Western blot analyses of CXCR4 protein levels in starved (0.1% serum) and serum-maintained (10% serum) cells treated with
2.5mM TSA for 1 day. The numbers at the bottom indicate the fold variations relative to the value of starved (st) MCF-7 cells. Immunoblot with anti-vinculin
antibody was used for normalisation. The experiments were repeated three times, with similar results. (C) Western blot analyses of CXCR4 protein levels in
cells treated with HGF with or without 2.5mM TSA for 1 or 2 days (d). Representative western blots are shown, and the numbers at the bottom indicate the
fold variations relative to the value of st MCF-7 cells. Immunoblot with anti-vinculin antibody was used for normalisation. The experiments were repeated
five times, with similar results, and the means±s.e. are reported in the histograms. *Po0.05, **Po0.005 and ***Po0.001 vs respective control values;
DDPo0.005 vs HGF-treated cells. (D) Western blot analyses of Met protein levels in cells treated with HGF with or without 2.5mM TSA for 1 or 2 days (d).
The numbers at the bottom indicate the fold variations relative to the respective st values. Immunoblot with anti-vinculin antibody was used for
normalisation. The blots are representative of experiments repeated three times.
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T h eb l o c k a d eo fH D A C sw i t hT S As e e m e dt oi n d u c eaf u n c t i o n a l
Met protein phosphorylated at the catalytic domain (Tyr 1349) mostly
in MDA-MB231 cells (7–15-folds increase). The mechanism might
be linked to receptor overexpression, making HGF ligand
binding unnecessary for receptor activation (Benvenuti and Como-
glio, 2007): the phosphoMet/Met ratios in TSA-treated and
starved cells were 7 and 2.5. Hepatocyte growth factor impaired the
increases in Met protein level and phosphorylation after TSA. In
MCF-7 cells, HGF or TSA treatment raised the Met protein level
(Figure 2D).
Effects of HGF treatment on signal-transduction pathways
possibly implicated in CXCR4-mediated invasion
Hepatocyte growth factor causes early direct molecular changes
and indirect late effects (Tacchini et al, 2000). We hypothesised
that the molecular effects of HGF leading to changes in
invasiveness and CXCR4 expression started before the Met
downregulation observed at 1 or 2 days in MDA-MB231 cells.
Therefore, we studied the time courses of the signalling pathways
possibly activated by HGF, and their roles in the changes of
invasiveness, of CXCR4 protein levels and of NF-kB trans-
activation (Figure 3). Nuclear factor-kB is one of the main
transcription factors in CXCR4 expression (Maroni et al, 2007;
Matteucci et al, 2007).
In MDA-MB231 cells, HGF transiently enhanced Met tyrosine
phosphorylation at 30min, similar to in MCF-7 cells (Figure 3A).
However, the phosphorylation patterns of ERK1/2, Akt and
c-Src were different in the two cell lines after HGF treatment
(Figure 3B). The numbers in the graphs were calculated using
the densitometric values of the western blots and taking as 1
the values of ERK1/2, Akt and c-Src protein levels unmodified by
HGF.
In HGF-treated MDA-MB231 cells, phosphoAkt/Akt (pAkt) and
phospho-c-Src/c-Src (pSrc) ratios increased starting from 30min
up to 24h. The phosphoERK1/2/ERK1/2 (pERK) ratio showed a
short-lasting rise at 30min (Figure 3B). In MDA-MB231 cells, Akt
migrates at approximately 60kDa as a tightly spaced triplet (Stoica
et al, 2003; Matteucci et al, 2007). We evaluated phosphoAkt using
an antibody directed against Ser 473 of the various isoforms. These
results suggested that the HGF/Met interaction, causing rapid
Met-tyrosine phosphorylation, regulated downstream transduction
pathways before Met receptor downregulation. Akt and c-Src
phosphorylations were persistently elevated in HGF-treated MDA-
MB231 cells, suggesting that these cell signalling pathways might
be important to regulate changes of invasiveness and CXCR4
expression. In contrast, in HGF-treated MCF-7 cells the pERK ratio
rapidly and persistently increased for up to 24h, while the pSrc
ratio enhancement was biphasic (Figure 3B).
To understand the role of protein kinases in CXCL12-mediated
chemoinvasion in HGF-treated MDA-MB231 cells, we analysed
the effect of specific inhibitors (Figure 3C). Hepatocyte growth
factor reduced chemoinvasion towards CXCL12 (85%), the
CXCR4 protein level (70%) and NF-kB transactivation (33%).
These inhibitory effects were enhanced by c-Src blockade with
SU6656, but prevented by Akt blockade, to different extents. The
MEK inhibitor PD 98059 (100mM) (Matteucci et al, 2005) had
no effect on HGF-induced changes (data not shown). These
findings suggested that c-Src inhibition might be important to
decrease CXCL12-mediated chemoinvasion, possibly involving
reduced NF-kB-dependent transactivation of CXCR4, and demon-
strated that c-Src inhibition had additive effects with HGF,
probably because they controlled different molecular mechanisms
in MDA-MB231 cell motility. The findings with the chemical
inhibitor of c-Src were confirmed using c-Src dominant negative
(data not shown).
Involvement of c-Src and ETS1 in the changes of CXCR4
transactivating activity induced by TSA
c-Src is a critical component of the pathways regulating
proliferation, survival and metastasis (through effects on adhesion,
invasion and motility), and is one of the Met-signal transducers
involved in the regulation of NF-kB activity (Huang et al, 2003a;
Yeatman, 2004; Mazzone and Comoglio, 2006). High protein levels
and/or catalytic activity of c-Src have been detected in a number of
human cancers, including breast carcinoma (Ishizawar and
Parsons, 2004). To investigate the functional role of c-Src in
TSA-treated cells, we examined endogenous c-Src expression and
CXCR4 transactivating activity after c-Src inhibition with SU6656
(Figure 4).
Transfection experiments were carried out with a construct
containing the 0.38kb fragment of the c-Src promoter SCR1A
(Figure 4A). The activity of this construct is negatively regulated
by HDAC inhibitors due to the presence of core-promoter
elements including TAF1 (Dehm et al, 2004). 0.38SRCLuc activity
was 10 times higher in MDA-MB231 than in MCF-7 cells (the
absolute value for Firefly/Renilla luciferase activity ratio was
2 10
 2 in MCF-7 cells). In MDA-MB231 cells, TSA treatment
reduced the activity of the c-Src promoter construct by 60%
(Figure 4A) and of endogenous c-Src protein level by 50%
(Figure 4C).
As shown in Figure 4B, the inhibition of basal c-Src activity with
SU6656 largely prevented (75%) the CXCR4 transactivating activity
of TSA-treated MDA-MB231 cells. The findings with the chemical
inhibitor of c-Src were confirmed using c-Src dominant negative
(data not shown). These results indicate the important role
of endogenous c-Src activity in MDA-MB231 cells for the
TSA-stimulatory effect on CXCR4 expression.
To further clarify the role of c-Src, experiments were carried out
using the Srcwt expression vector (Figure 4C and D). Similar to
HGF treatment, Srcwt permits an evaluation of the effects of
enhanced c-Src activity. In fact, the highly expressed exogenous
c-Src was phosphorylated, therefore active (Figure 4C).
Thus, in MDA-MB231 cells, Srcwt reduced the basal CXCR4
transactivating activity, possibly by increasing c-Src formation,
and interfered with the activation of CXCR4Luc by TSA. In
contrast, it was stimulatory on CXCR4Luc in MCF-7 cells
(Figure 4D).
To deepen the knowledge of the transcriptional mechanism(s)
responsible for the increase in CXCR4 transactivation after TSA
treatment in MDA-MB231 cells, we examined ETS1 luciferase
activity (Figure 4E and F). Trichostatin A enhanced ETS1 multimer
construct activity in MDA-MB231 cells (seven-fold), indicating a
key role of this transcription factor (Figure 4E). The ETS1
dominant negative completely prevented CXCR4( 2632/
þ86)Luc activation by TSA in MDA-MB231 cells (Figure 4F).
TSA modulated signal-transduction pathways and genes
for apoptosis in MDA-MB231 cells
To obtain more information on transcription factors in TSA effects,
we studied NF-kB transactivating activity. Nuclear factor-kB seems
important for CXCR4 expression (Maroni et al, 2007; Matteucci
et al, 2007) and, depending on cell conditions, it can regulate the
triggering of apoptosis (Beere, 2004; Luo et al, 2005). Therefore, we
examined TSA effect on cell signalling and genes implicated in
apoptosis (Figure 5).
In MDA-MB231 cells, 2.5mM TSA reduced NF-kB transactivation
by about 80% (Figure 5A) and the level of phosphorylated (active)
Akt (Figure 5B). Opposite effects were seen in MCF-7 cells (Figure
5A and B).
To investigate how Met might be involved in the changes of
protein-kinase transducers after TSA, we knocked down the
receptor by siRNA-Met in MDA-MB231 cells (Figure 5C). This
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did not prevent the changes of c-Src and Akt and their
phosphorylated forms. Antiluciferase-siRNA transfection did not
affect the Met control value (not shown).
We verified whether TSA induced apoptosis in MDA-MB231
cells under our experimental conditions (Figure 5D).
Cytofluorimetric analysis and JC-1 assay showed that MDA-
MB231 cells had a background level of apoptosis of about 2.5%, in
agreement with the literature (Toillon et al, 2002). Treatment with
0.1 and 2.5mM TSA for 1 or 2 days raised the percentage of
apoptosis (about 6–10% on day 1, and 7–12% on day 2). Necrotic
cell death (about 5%) was also observed on day 2 with the higher
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Figure 3 Changes in signalling pathways after HGF. (A) Total cell extracts from starved (st) and HGF-treated cells were immunoprecipitated using anti-
Met antibody, and immunoblotted with anti-Met and anti-phosphotyrosine (p-Tyr) antibodies. The experiments were repeated three times, with similar
results. (B) MCF-7 and MDA-MB231 cells were exposed to HGF for various times, and western blots of total proteins were performed in triplicate.
Representative western blots are shown. Densitometric analysis was carried out for each cell line, ERK1/2, Akt and c-Src protein levels were not changed by
HGF, and were taken as 1. The graphs show phosphoERK1/2/ERK1/2 (pERK1/2), phosphoAkt/Akt (pAkt) and phospho-c-Src/c-Src (pSrc) ratios in starved
(J) and HGF-treated (K) MCF-7 cells and in starved (n) and HGF-treated (m) MDA-MB231 cells. The data are the means±s.e. of experiments repeated
three times. *Po0.05, **Po0.005 and ***Po0.001 vs respective values for st cells. (C) MCF-7 and MDA-MB231 cells pretreated with HGF for 24h, with
or without 2mM c-Src or 8mM Akt inhibitor, were used for the Matrigel invasion assay, with CXCL12 in the bottom chamber. We estimated invasion by
counting the invading cells on the lower side of the membrane after staining ( 200 magnification of selected fields). The experiments were repeated three
times. The numbers at the bottom indicate the means of migrated cells of 10 fields±s.e. *Po0.05 and ***Po0.001 vs st cells. Western blot analysis of
CXCR4 protein levels in 24h HGF-treated cells, with or without c-Src or Akt inhibitor. The numbers at the bottom indicate the means±s.e. of three
experiments. *Po0.05 and ***Po0.001 vs st cells. Cells transfected with NF-kBLuc were exposed to HGF for 24h, with or without c-Src or Akt inhibitor.
The histograms indicate the absolute values for ratios of Firefly/Renilla luciferase activity. The data are the means±s.e. of five independent experiments
performed in triplicate. *Po0.05 and ***Po0.001 vs control value; 1Po0.05 and 111Po0.001 vs HGF-treated cells.
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sdose of TSA. Neither TSA dose was apoptotic in MCF-7 cells, and
HGF did not give any hallmarks of apoptosis in either cell line (not
shown). Dot plots for cytofluorimetric analysis of MCF-7 and
MDA-MB231 cells are reported in Supplementary Figure 1C.
To further characterise the TSA-induced apoptotic response,
which seemed to be limited to the invasive MDA-MB231 cells, we
examined the expression of proapoptotic genes (Figure 5E). These
were caspase 3, highly expressed in MDA-MB231 cells, caspase 8,
prevalent in MCF-7 cells, and Bax, which is activated by TSA
(Huang et al, 2003b; Singh et al, 2005; Yang et al, 2007). In MDA-
MB231 cells, procaspase 3 (32kDa) and 8 (50kDa) protein levels
were practically unchanged, except that procaspase 3 slightly
declined 2 days after both TSA doses. Correlated with apoptosis at
1 and 2 days, we observed 17 and 20kDa cleavage fragments for
caspase 3, using 0.1 and 2.5mM TSA, and 20kDa cleavage fragment
for caspase 8, using 2.5mM TSA. Bax protein expression was
enhanced (2–2.6-folds) after both TSA doses. As expected, the
proapoptotic genes were not affected by TSA in MCF-7 cells (not
shown).
DISCUSSION
The main points that call for discussion regard the highly invasive/
metastatic MDA-MB231 cells and consist in the HGF-dependent
reduction of invasion mediated by CXCL12 due to reduction of
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Figure 4 Effects of c-Src and ETS1 on TSA-induced changes of CXCR4 transactivating activity. (A) Cells transfected with 0.38SRCLuc were exposed to
2.5mM TSA in medium containing 10% FBS. The histograms indicate the fold variations of luciferase activity relative to MCF-7 control value, taken as 1. The
data are the means±s.e. of five independent experiments performed in triplicate. ***Po0.001 vs MCF-7 control value;
DDPo0.005 and
DDDPo0.001 for
TSA treatment vs respective values for controls. (B) Cells transfected with pCXCR4( 2632/þ86)Luc were exposed to 2.5mM TSA with or without 2mM c-
Src inhibitor in medium containing 10% FBS. The histograms indicate the absolute values for ratios of Firefly/Renilla luciferase activity. The data are the
means±s.e. of three independent experiments performed in triplicate. *Po0.05, **Po0.005 and ***Po0.001 vs respective values for controls; 1Po0.05
and 111Po0.001 vs TSA-treated cells. (C) Total proteins were extracted 1 day after Srcwt transfection and 2.5mM TSA treatment, and were analysed by
western blot. Immunoblot with anti-c-Src or anti phospho-c-Src (pSrc) antibody was carried out, and the numbers at the bottom indicate the fold variations
relative to the MCF-7 control value. Immunoblot with anti-vinculin antibody was used for normalisation. Experiments were repeated three times, with similar
results. (D) Cells were co-transfected with pCXCR4( 2632/þ86)Luc and Srcwt expression vector, and exposed or not to 2.5mM TSA in medium
containing 10% FBS. The histograms indicate the absolute values for ratios of Firefly/Renilla luciferase activity. The data are the means±s.e. of three
independent experiments performed in triplicate. *Po0.05, **Po0.005 and ***Po0.001 vs respective control value;
DPo0.05 vs Srcwt-transfected MDA-
MB231 cells. (E) MDA-MB231 cells transfected with ETS1Luc were exposed to 2.5mM TSA in medium containing 10% FBS. The histograms indicate the
absolute values for ratios of Firefly/Renilla luciferase activity. The data are the mean±s.e. of five independent experiments performed in triplicate.
**Po0.005 vs control value. (F) Cells co-transfected with pCXCR4( 2632/þ86)Luc and DETS1 were exposed to 2.5mM TSA in medium containing 10%
FBS. The histograms indicate the absolute values for ratios of Firefly/Renilla luciferase activity. The data are the means±s.e. of three independent
experiments performed in triplicate. ***Po0.001 vs control value; 111Po0.001 vs TSA-treated cells.
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sCXCR4 levels and function. Interestingly, HDACs played a
regulatory role in the reduction of CXCR4 expression that involved
critical mechanisms such as enhancement of c-Src and decrease of
NF-kB activities. It is worth noting that the blockade of HDACs
with TSA induced CXCR4 and Met genes for invasiveness, but also
triggered apoptosis through inactivation of the phosphoAkt/NF-kB
pathway, partly reducing the number of migrated MDA-MB231
cells. Metastatic cancer cells acquire a motile phenotype to
penetrate tissues and vasculature, and adopt survival mechanisms
to avoid apoptosis (Mehlen and Puisieux, 2006). Histone
deacetylase blockade seemed to modify both these aspects of the
aggressive phenotype (Boyault et al, 2007). In MCF-7 low-invasive
cells, HGF typically enhanced chemoinvasion towards CXCL12,
and we found no hallmarks of apoptosis after HDAC blockade.
First, MDA-MB231 cells showed spontaneous mesenchymal
movement, related to the key function of proteolytic enzymes (Guo
et al, 2002; Wolf et al, 2008), that decreased after HGF exposure.
One explanation might be that HGF reduces ETS1 activity, possibly
affecting the expression of target genes such as proteolytic
enzymes (Guo et al, 2002; Maroni et al, 2007; Furlan et al, 2008).
In addition, HGF largely impaired the striking migration towards
CXCL12, that is, specific chemoinvasion, as a consequence of the
diminished CXCR4 expression. In the presence of CXCL12, both
the inhibitory effects of HGF might be evident.
The early changes in Met phosphorylation after HGF and the
persistent activation of transduction-signalling pathways down-
stream, including c-Src and Akt phosphorylation, seemed to be
involved in the later decrease of CXCR4 expression. We have
previously suggested that in HGF-treated MDA-MB231 cells
phospho-c-Src activates HDAC3 (Matteucci et al, 2007), and
phosphoAkt stabilizes HDAC3 (Zeng et al, 2006). As a corepressor
of NF-kB (Chen et al, 2001; Gao et al, 2005), HDAC3 probably
intervenes in the inhibitory regulation of CXCR4 promoter
activity. Nuclear factor-kB is one of the principal transcription
factors in CXCR4 expression (Maroni et al, 2007; Matteucci et al,
2007).
We showed that HDACs might really be involved in the HGF-
dependent decrease of CXCR4 expression and of chemoinvasion
towards CXCL12. Trichostatin A, a competitive inhibitor of
HDACs, did in fact reduce the inhibitory effect of HGF on CXCR4
expression and invasiveness. The experimental evidence using a
c-Src inhibitor showed that the depletion of endogenous c-Src
activity cooperated with HGF to reduce MDA-MB231 cell
invasiveness/CXCR4 expression/NF-kB transactivation. Our
findings suggest that different molecular mechanisms controlled
by c-Src, both after HGF activation and under basal conditions,
intervened in NF-kB activity regulation. c-Src maintains NF-kB
activity through tyrosine phosphorylation of I-kB kinase a/b
(Huang et al, 2003a), besides activating HDAC3 (Matteucci et al,
2007).
In contrast with c-Src inhibition, the Akt inhibitor hindered
HGF inhibitory effects, indicating that Akt activity participated in
HGF-reduction of MDA-MB231 cell invasiveness regulating
CXCR4 expression through NF-kB (deGraffenried et al, 2004).
These findings thus point to the HGF–HDAC interaction as a
further mechanism by which the microenvironment influences
the tumour invasive/metastatic phenotype at epigenetic level
(Matteucci et al, 2007; Matsumoto et al, 2008). The HGF-
dependent decrease in CXCR4 function in MDA-MB231 cells
seemed to support our idea that HGF, possibly produced at
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Figure 5 Proapoptotic role of TSA in MDA-MB231 cells. (A) Cells transfected with NF-kBLuc were exposed to 2.5mM TSA in medium containing 10%
FBS. The histograms indicate the absolute values for ratios of Firefly/Renilla luciferase activity. The data are the means±s.e. of five independent experiments
performed in triplicate. ***Po0.001 vs MCF-7 control value;
DDDPo0.001 vs MDA-MB231 control value. (B) The cells were exposed to 2.5mM TSA for 1
or 2 days (d), and western blots of total proteins were carried out. The numbers at the bottom indicate the fold variations relative to the respective values
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repeated three times. (D) The histograms show the percentages of apoptotic and necrotic cells obtained by cytofluorimetric analysis of TSA-treated cells.
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and ***Po0.001 vs control values at 1 and 2 days. (E) The cells were treated with TSA, and total protein extracts were prepared and used for western
blots. The numbers at the bottom indicate the fold variations relative to controls. Immunoblot with anti-vinculin antibody was used for normalisation. The
blots are representative of experiments repeated three times.
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ssecondary growth site(s), might enhance the homing of metastatic
cells attracted by CXCL12 to specific districts such as bones and
lymph nodes (Balkwill, 2004). The site of metastasis depends on
the characteristics of neoplastic cells and of the permissive
microenvironment in the metastatic target organ for incoming
cancer cells (Yilmaz et al, 2007). Chemokines and growth factors,
such as HGF, seem to act as mediators between the tumour
microenvironment and the neoplastic cells, and are important in
tumour progression and metastasis (Matsumoto and Nakamura,
2006; Benvenuti and Comoglio, 2007; Desiderio, 2007; Singh et al,
2007).
Second, we examined the mechanistic basis of the differences in
breast tumour cell responses to TSA, depending on tumour
aggressiveness, and considered the transcriptional regulation of
CXCR4 and Met, two genes important for tumour cell invasiveness
(Benvenuti and Comoglio, 2007; Furlan et al, 2008). The growing
list of non-histone proteins regulated by acetylation/deacetylation
comprises more than 30 transcription factors including NF-kB and
ETS1 (Pazin and Kadonaga, 1997; Gao et al, 2005; Ducasse and
Brown, 2006; Ropero and Esteller, 2007; Wang et al, 2007). Six
ETS1 and one NF-kB-binding sites are present in the CXCR4
promoter (Maroni et al, 2007), and their contribution to CXCR4
expression might depend on different transcription factor
activities in MDA-MB231 and MCF-7 cells. Nuclear factor-kB
activity is regulated by post-translational modifications, and
HDAC inhibitors might activate NF-kB by maintaining high levels
of acetylation (Mayo et al, 2003), as probably occurred in MCF-7
cells. At a difference, in MDA-MB231 cells with a constitutively
active NF-kB (Matteucci et al, 2007), p52 subunit acetylation after
TSA may well prevent nuclear p65 DNA binding (Hu and Colburn,
2005). Studies in progress in our laboratory show that p52 is
acetylated in MDA-MB231 cells transfected with siRNAs for HDACs
1 and 3. The inhibition of NF-kB activity seemed to explain
the small enhancement of CXCR4 transactivation after TSA in
MDA-MB231 cells, although serum culture-conditions also influence
this. Other transcription factors such as ETS1 might be activated by
HDAC blockade, regulating CXCR4 transactivation in MDA-MB231
cells. Sites enriched in acetylated histone 3 act as enhancer
regulating ETS1 sequences in uPA promoter (Wang et al,2 0 0 7 ) .
Interconnected molecular events orchestrated by ETS1 in breast
tumour cells converge to promote invasion of their matrix
environment. The ETS1 appears to favour HGF signalling by
triggering HGF activation from the precursor and its receptor Met
overexpression, due to the presence of numerous (four) ETS1
sequences (Benvenuti and Comoglio, 2007; Furlan et al, 2008). The
ETS1 overexpression promotes malignancy through HGF/Met-
mediated motility, which allows breast cancer cells to bypass the
requirement of promigratory signals supplied by the environment
(such as fibronectin) for invading (Furlan et al, 2008).
Thus, we suggest that HDAC inhibitors are involved indirectly in
Met and CXCR4 induction by controlling the activities of
transcription factors with different mechanisms that possibly
depended on carcinoma cell aggressiveness. They included NF-kB
subunit acetylation, which is currently being studied, and/or
ETS1/NF-kB cooperation (Maroni et al, 2007). The demonstration
of CXCR4 transactivation using a promoter construct, which is
likely to have altered nucleosome structures, would exclude the
involvement of acetylated histones H3 and H4 after TSA treatment.
Third, our data indicate that the marked decrease of c-Src
expression was a key event for TSA effect on the cellular and
molecular parameters, including the decrease in the pAkt/Akt ratio
in MDA-MB231 cells. The decrease in c-Src expression after HDAC
inhibition is more likely direct and results from acetylation of non-
histone factors associated with the c-Src promoter (Dehm et al,
2004). Reduced c-Src activity is involved in PTEN activation and
Akt activity inhibition (Lu et al, 2003; Pan et al, 2007). However,
some effects such as Akt dephosphorylation might also be
facilitated by TSA, which alters the dynamics of HDAC-protein
phosphatase 1 (Chen et al, 2005).
The reductions of c-Src expression, pAkt/Akt ratio and NF-kB
activity in TSA-treated MDA-MB231 cells probably contributed to
the apoptotic switch, and to the drop in the number of migrated
cells. We cannot exclude that TSA might directly affect the
function of cytoskeleton proteins and motility (Boyault et al,
2007). Only in MDA-MB231 cells did the two doses of TSA (0.1 and
2.5mM) cause a small percentage of apoptosis, consistent with
activation of proapoptotic genes. There are conflicting data on the
role of ETS1 in apoptosis (Dittmer, 2003).
Finally, some HGF/Met transduction signals seemed to compete
with that triggered by TSA, with opposite effects on chemoinvasion
and CXCR4 expression in MDA-MB231 cells. These quite likely
consisted in the HGF-dependent enhancement of c-Src phosphory-
lation, which counteracted the reductions of c-Src transactivation
and protein level due to TSA. Srcwt transfection, by increasing
active c-Src, reduced the stimulatory effect of TSA on CXCR4
transactivation. Hepatocyte growth factor and TSA had opposite
effects on Akt phosphorylation, which seems to have an important
influence on the pro- and antiapoptotic role of NF-kB (Mayo et al,
2003; Beere, 2004; Luo et al, 2005).
In conclusion, HDACs participated in the molecular events
activated by HGF, leading to reduction of specific invasiveness in
MDA-MB231 cells. Clearly, therefore, the potential therapeutic use
of TSA should take into account the differences in the aggressive-
ness of breast carcinoma cells and the tumour microenvironment
at the secondary growth site, where HGF might contribute to
creating a permissive niche for homing.
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